|
|
 Tuesday, May 17, 2011 / Oraya Completes Enrollment in Sham-Controlled Study of Radiation for Wet AMD Oraya Therapeutics, Inc. today announced that it has completed enrollment of its INTREPID clinical trial in Europe. The study is the first sham-controlled, double-masked trial to evaluate the effectiveness and safety of radiation therapy in conjunction with standard of care anti-VEGF injections for the treatment of wet age-related macular degeneration (AMD).Monday, February 28, 2011 / King’s College Hospital First to Trial New Radiation Eye Treatment http://www.kch.nhs.uk/news/archive/2010/kings-college-hospital-first-to-trial-new-radiation-eye-treatment/Wednesday, April 07, 2010 / Oraya Therapeutics Granted European CE Mark for the IRay Stereotactic Radiotherapy System Oraya Therapeutics, Inc. announces today that a leading European notified body has granted approval to designate the CE mark to Oraya’s IRay stereotactic radiotherapy system. Under development since 2007, the IRay is designed specifically to treat diseases of the eye, and the technology enables precise delivery of low energy X-rays for the treatment of wet age-related macular degeneration.Tuesday, January 05, 2010 / Oraya Therapeutics Initiates First Ever Sham-Controlled Study of Radiation Therapy for Wet AMD Oraya Therapeutics Initiates First Ever Sham-Controlled Study of Radiation Therapy for Wet AMD.Tuesday, October 20, 2009 / Oraya Therapeutics to present at Ophthalmology Innovations Summit The Ophthalmology Innovation Summit (OIS), to be held at the Palace Hotel in San Francisco on October 22, 2009, will bring together leaders in the development of ophthalmic products, drugs, and devices. Oraya therapeutics will present a summary of its innovative technology, currently undergoing clinical evaluation for the treatment of wet macular degeneration. Additional information can be found at http://www.ophthalmologysummit.com.Tuesday, August 04, 2009 / Oraya Therapeutics Names JIM TAYLOR as President and Chief Executive Officer Appointment of seasoned executive will support development of company's age-related macular degeneration treatmentMonday, July 20, 2009 / Oraya Therapeutics Raises $42 MILLION in Series C Financing Company to begin international multi-center clinical trials for age-related macular degeneration treatment |
Copyright © 2009 Oraya Therapeutics, Inc. All rights reserved. | (510) 456-3700 | info@orayainc.com
Note: The IRay™ System is an investigational device and not available in the US.
Note: The IRay™ System is an investigational device and not available in the US.